The estimated Net Worth of Scott Bizily is at least 295 千$ dollars as of 19 August 2024. Dr Bizily owns over 500 units of 4D Molecular Therapeutics stock worth over 114,457$ and over the last 2 years he sold FDMT stock worth over 180,126$.
Sign up
Dr D FDMT stock SEC Form 4 insiders trading
Dr has made over 16 trades of the 4D Molecular Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 500 units of FDMT stock worth 3,245$ on 19 August 2024.
The largest trade he's ever made was exercising 8,153 units of 4D Molecular Therapeutics stock on 1 April 2024 worth over 102,239$. On average, Dr trades about 2,569 units every 31 days since 2022. As of 19 August 2024 he still owns at least 7,281 units of 4D Molecular Therapeutics stock.
You can see the complete history of Dr Bizily stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Scott P. Bizily J.D., Ph.D. biography
Dr. Scott P. Bizily J.D., Ph.D. is the Chief Legal Officer at 4D Molecular Therapeutics.
What's Dr D's mailing address?
Scott's mailing address filed with the SEC is C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE, CA, 94608.
Insiders trading at 4D Molecular Therapeutics
Over the last 4 years, insiders at 4D Molecular Therapeutics have traded over 22,158,915$ worth of 4D Molecular Therapeutics stock and bought 2,479,347 units worth 51,074,981$ . The most active insiders traders include Global Investors Lp Viking ...、John F Milligan、Global Investors Lp Viking .... On average, 4D Molecular Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of 1,516,666$. The most recent stock trade was executed by Scott Bizily on 19 August 2024, trading 500 units of FDMT stock currently worth 3,245$.
What does 4D Molecular Therapeutics do?
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
What does 4D Molecular Therapeutics's logo look like?
Complete history of Dr Bizily stock trades at 4D Molecular Therapeutics
4D Molecular Therapeutics executives and stock owners
4D Molecular Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. David H. Kirn,
Co-Founder, CEO, Pres & Director -
August J. Moretti Esq., J.D.,
Chief Financial Officer -
August J. Moretti,
Chief Financial Officer -
Dr. Robert S. Fishman,
Chief Medical Officer & Therapeutic Area Head of Pulmonology -
Dr. David E. Schaffer Ph.D.,
Co-Founder, Chief Scientific Advisor & Independent Director -
Dr. John F. Milligan,
Exec. Chairman -
Dr. Nadine Greiner Ph.D.,
Chief HR Officer -
Dr. Scott P. Bizily J.D., Ph.D.,
Chief Legal Officer -
Dr. Raphael Schiffmann M.D.,
Sr. VP & Therapeutic Area Head of Cardiology -
Jessica Wilan,
Sr. VP of HR -
Dr. Peter Francis B.Sc., M.D., Ph.D.,
Chief Scientific Officer & Head of Ophthalmology Therapeutic Area -
Dr. Fred Kamal Ph.D.,
COO & CTO -
Theresa Janke,
Co-Founder & Chief Strategy Officer -
Scott Bizily,
Chief Legal Officer -
August J Moretti,
Chief Financial Officer -
Tony Dung Ling Yao,
Director -
Noriyuki Kasahara,
Director -
Carolyne Zimmermann,
Chief Business Officer -
Robert Young Kim,
Chief Medical Officer -
Fariborz Kamal,
President and COO -
Uneek Mehra,
See Remarks -
David Schaffer,
Director -
Robert S Fishman,
Chief Medical Officer -
John F Milligan,
-
Susannah Gray,
-
Nancy Miller Rich,
-
David Kirn,
Chief Executive Officer -
Jacob Chacko,
-
Global Investors Lp Viking ...,
-
Charles Theuer,
-
Shawn Tomasello,